Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Evolent Health Q1 2026 Earnings Call - Strong Q1 Execution Masks Exchange Headwinds, Performance Suite Dominates Growth
Evolent Health delivered a solid first quarter, with revenue of $496 million and adjusted EBITDA of $22 million, landing in line with expectations. The core narrative is one of disciplined execution a...
- Revenue of $496 million grew 9% sequentially (ex-ECP), while adjusted EBITDA came in at $22 million, meeting expectations.
- Medical Expense Ratio (MER) improved 150 basis points to 93%, supported by favorable prior year development that offset higher oncology prevalence.
- Performance Suite revenue surged 26% sequentially to $323 million, driven by the new Aetna launch and membership growth.
- +7 more takeaways
Primo Brands Q1 2026 Earnings Call - Direct Delivery Turnaround Drives Raised Growth Guidance
Primo Brands delivered a strong start to 2026, with first quarter comparable net sales rising 1.7% to $1.63 billion, driven by broad-based price mix and volume gains. The company raised its full year ...
- Comparable net sales grew 1.7% year-over-year to $1.63 billion, marking a return to top-line growth driven by price mix and volume.
- Full year comparable organic net sales guidance raised to 1%-3% from flat to 1%, reflecting stronger-than-expected first quarter performance.
- Direct delivery service levels improved significantly, with on-time-in-full rates exceeding 90% and customer net adds approaching breakeven in March.
- +7 more takeaways
Teleflex Q1 2026 Earnings Call - Divestitures on Track, New CEO Hired, and Margin Pressure from Recalls
Teleflex delivered a mixed first quarter, with revenue growth beating expectations but adjusted EPS falling as margin pressure mounted from tariffs and a third-party supplier recall. The company is ex...
- Teleflex Q1 2026 revenue grew 5.1% on a pro forma adjusted constant currency basis to $548.3 million, beating internal expectations and tracking within the 4.5%-5.5% full-year guidance range.
- Adjusted EPS fell 3.5% year-over-year to $1.39 due to margin pressure from tariffs, higher interest expense, and quality remediation charges linked to a third-party supplier recall.
- The company announced the appointment of Jason Weidman as the next President and CEO, effective June 8, 2026, bringing over 25 years of medical technology experience from Medtronic.
- +7 more takeaways
Alvotech Q1 2026 Earnings Call - Pipeline Resubmission and Manufacturing Diversification Drive 2027 Growth Outlook
Alvotech navigated a transitional quarter in Q1 2026, with revenues declining 20% year-over-year to $106 million as the company deliberately slowed production at its Reykjavik facility to address FDA ...
- Q1 2026 revenues declined 20% YoY to $106 million, driven by production slowdowns at the Reykjavik facility and timing of licensing milestones.
- Adjusted EBITDA came in at $24 million (23% margin), up from $21 million in Q1 2025, cushioned by licensing revenue and cost management.
- FDA is conducting a routine GMP surveillance inspection at the Reykjavik site, expected to close by end of day tomorrow; no new findings anticipated.
- +12 more takeaways
ESAB Corporation Q1 2026 Earnings Call - Record Sales and Strategic Acquisitions Drive Margin Expansion
ESAB Corporation reported record first quarter 2026 sales of $715 million, reflecting a 10% year-over-year increase driven by strong performance across its diversified global footprint. The company ge...
- Record Q1 2026 sales of $715 million, up 10% year-over-year, driven by strong execution and diversified global footprint.
- Adjusted EBITDA of $136 million, up 6% year-over-year, with adjusted EBITDA margin of 19%.
- Acquisitions EWM and Aktiv both grew double digits year-over-year, demonstrating strong integration and market momentum.
- +7 more takeaways
Zai Lab Q1 2026 Earnings Call - Zoci Data Strengthens Global BLA Path While Regional Revenue Faces Near-Term Pressure
Zai Lab reported a 6% year-over-year decline in Q1 2026 product revenue to $99.6 million, driven by generic competition for ZEJULA and price discounts on VYVGART, though the company expects sequential...
- Zoci demonstrated a 62.5% confirmed intracranial overall response rate in extensive-stage small cell lung cancer, with a best overall intracranial response rate approaching 69% and only 16% grade 3 or higher treatment-related adverse events, signaling a best-in-class safety and efficacy profile.
- The registrational Phase III DLLEVATE study for zoci is enrolling well and is on track to complete enrollment in the first half of 2027, positioning the company for an interim analysis and potential accelerated approval submission in 2028.
- Zai Lab announced global collaborations with Amgen and Boehringer Ingelheim to explore zoci in combination with T-cell engagers and PD-L1 inhibitors, leveraging complementary mechanisms to deepen and extend responses in small cell lung cancer.
- +12 more takeaways
Apyx Medical Q1 2026 Earnings Call - AYON Sales Surge Drives 32% Revenue Growth and Upward Guidance Revision
Apyx Medical delivered a robust first quarter, with total revenue jumping 32% year-over-year to $12.5 million, fueled by a 36% surge in surgical aesthetics sales. The AYON body contouring platform, la...
- Total revenue grew 32% year-over-year to $12.5 million, driven by a 36% increase in surgical aesthetics segment revenue to $10.7 million.
- AYON body contouring system sales are ramping rapidly, with approximately 80% of sales going to existing Renuvion customers and new accounts showing strong engagement.
- GLP-1 weight loss drug adoption is creating a structural tailwind, as patients seek surgical interventions for loose skin, with management citing early-stage adoption and significant long-term demand potential.
- +9 more takeaways
Victory Capital Q1 2026 Earnings Call - Record Flows and Aggressive Buybacks Fuel Growth
Victory Capital reported record-breaking first quarter results, driven by a massive $18.9 billion in long-term gross flows and a 77% year-over-year revenue jump to $388 million. The firm is clearly ca...
- Record Q1 2026 gross flows hit $18.9 billion, a 104% increase year-over-year, signaling strong distribution momentum.
- Total client assets reached $313 billion, with international AUM growing to $55 billion across 60 countries.
- VictoryShares ETF AUM surged 53% year-over-year to over $20 billion, with net flows of $1.3 billion for the quarter.
- +7 more takeaways
Polestar Q1 2026 Earnings Call - Record Volume Growth Amidst Margin Squeeze and Tariff Headwinds
Polestar delivered a record first quarter with 13,100 vehicles sold, marking a 7% year-over-year increase driven by strong regional performance in Europe and successful launch of the Polestar 4. The c...
- Polestar achieved record Q1 2026 deliveries of 13,100 vehicles, a 7% year-over-year increase, with Europe accounting for 78% of total sales.
- Revenue remained stable at $633 million, supported by higher volume and positive foreign exchange impacts from the pound and euro.
- Gross margin contracted to negative 3.2%, pressured by intense EV competition, pricing discounts, lower carbon credit sales, and new EU/U.S. tariffs.
- +7 more takeaways
HMH Holding Q1 2026 Earnings Call - Offshore Contracting Inflection Drives Backlog Surge and Margin Resilience
HMH Holding reported a first quarter where revenue missed the top line but margins held firm, a classic signal of a supply chain and backlog transition. The real story is the 1.3 book-to-bill ratio an...
- HMH Holding reported Q1 2026 revenue of $171 million, down 14% year-over-year, driven by lower product and service volumes as the company navigates a transitional backlog period.
- Adjusted EBITDA came in at $30 million, with margins expanding to 17.6% year-over-year, a testament to disciplined cost execution and a favorable mix in spare parts.
- Orders surged to $218 million, a 10% increase year-over-year, resulting in a book-to-bill ratio of 1.3 times and signaling a clear inflection point in customer demand.
- +7 more takeaways